

Additional file 5. Multivariate analysis of patient baseline characteristics for the effect of interaction with axitinib titration on OS

Parameter	Titration	Covariate	Interaction	HR for Covariate	
	HR (95% CI) <i>p</i> -value ^a	HR (95% CI) <i>p</i> -value ^a	HR (95% CI) <i>p</i> -value ^a	Placebo Titration	Axitinib Titration ^b
Metastatic site (≥3 vs. ≤2)	0.131 (0.034–0.510) <i>p</i> =0.0033	2.191 (1.145–4.193) <i>p</i> =0.0179	2.026 (0.636–6.449) <i>p</i> =0.2321	2.191	4.438
Time from histopathological diagnosis to treatment (<1 vs. ≥1 year)		1.437 (0.701–2.943) <i>p</i> =0.3218	2.484 (0.868–7.112) <i>p</i> =0.0900	1.437	3.569
Baseline Hb <LLN (yes vs. no)		0.940 (0.484–1.823) <i>p</i> =0.8543	3.595 (1.315–9.824) <i>p</i> =0.0126	0.940	3.378

Abbreviations: *CI* confidence interval, *Hb* haemoglobin, *HR* hazard ratio, *LLN* lower limit of normal

^a *p*-values from 2-sided Wald test.

^b Hazard ratio for each covariate in the axitinib titration arm is derived from the multiplicity of the covariate hazard ratio and the interaction hazard ratio.